State-of-the-Art: Hypo-responsiveness to Oral Antiplatelet Therapy in Patients with Type 2 Diabetes Mellitus

Dharam J Kumbhani; Steven P Marso; Carlos A. Alvarez; Darren K McGuire

doi:10.1007/s12170-014-0430-5

State-of-the-Art: Hypo-responsiveness to Oral Antiplatelet Therapy in Patients with Type 2 Diabetes Mellitus

Dharam J Kumbhani, Steven P Marso, Carlos A. Alvarez, Darren K McGuire

Research output: Contribution to journal › Article

5 Scopus citations

Abstract

Diabetes mellitus is a global pandemic, associated with a high burden of cardiovascular disease. There are multiple platelet derangements in patients with diabetes, and antiplatelet drugs remain the first-line agents for secondary prevention as well as for high-risk primary prevention among patients with diabetes. This review provides a summary of oral antiplatelet drug hypo-responsiveness in patients with diabetes, specifically aspirin and clopidogrel resistance. Topics discussed include antiplatelet testing, definitions used to define hypo-response and resistance, its prevalence, association with clinical outcomes, and strategies to mitigate resistance. The role of prasugrel and ticagrelor, as well as investigational agents, is also discussed.

Original language	English (US)
Journal	Current Cardiovascular Risk Reports
Volume	9
Issue number	2
DOIs	https://doi.org/10.1007/s12170-014-0430-5
State	Published - 2015

Keywords

Antiplatelet
Antiplatelet resistance
Aspirin resistance
Clopidogrel resistance
Diabetes mellitus
High on-treatment platelet reactivity
Platelets

ASJC Scopus subject areas

Pharmacology (medical)
Pharmacology

Access to Document

10.1007/s12170-014-0430-5

Fingerprint Dive into the research topics of 'State-of-the-Art: Hypo-responsiveness to Oral Antiplatelet Therapy in Patients with Type 2 Diabetes Mellitus'. Together they form a unique fingerprint.

Cite this

Kumbhani, D. J., Marso, S. P., Alvarez, C. A., & McGuire, D. K. (2015). State-of-the-Art: Hypo-responsiveness to Oral Antiplatelet Therapy in Patients with Type 2 Diabetes Mellitus. Current Cardiovascular Risk Reports, 9(2). https://doi.org/10.1007/s12170-014-0430-5

@article{64894e7a88c244f980ce42ac653e5ccc,

title = "State-of-the-Art: Hypo-responsiveness to Oral Antiplatelet Therapy in Patients with Type 2 Diabetes Mellitus",

abstract = "Diabetes mellitus is a global pandemic, associated with a high burden of cardiovascular disease. There are multiple platelet derangements in patients with diabetes, and antiplatelet drugs remain the first-line agents for secondary prevention as well as for high-risk primary prevention among patients with diabetes. This review provides a summary of oral antiplatelet drug hypo-responsiveness in patients with diabetes, specifically aspirin and clopidogrel resistance. Topics discussed include antiplatelet testing, definitions used to define hypo-response and resistance, its prevalence, association with clinical outcomes, and strategies to mitigate resistance. The role of prasugrel and ticagrelor, as well as investigational agents, is also discussed.",

keywords = "Antiplatelet, Antiplatelet resistance, Aspirin resistance, Clopidogrel resistance, Diabetes mellitus, High on-treatment platelet reactivity, Platelets",

author = "Kumbhani, {Dharam J} and Marso, {Steven P} and Alvarez, {Carlos A.} and McGuire, {Darren K}",

year = "2015",

doi = "10.1007/s12170-014-0430-5",

language = "English (US)",

volume = "9",

journal = "Current Cardiovascular Risk Reports",

issn = "1932-9520",

publisher = "Current Medicine Group",

number = "2",

}

TY - JOUR

T1 - State-of-the-Art

T2 - Hypo-responsiveness to Oral Antiplatelet Therapy in Patients with Type 2 Diabetes Mellitus

AU - Kumbhani, Dharam J

AU - Marso, Steven P

AU - Alvarez, Carlos A.

AU - McGuire, Darren K

PY - 2015

Y1 - 2015

N2 - Diabetes mellitus is a global pandemic, associated with a high burden of cardiovascular disease. There are multiple platelet derangements in patients with diabetes, and antiplatelet drugs remain the first-line agents for secondary prevention as well as for high-risk primary prevention among patients with diabetes. This review provides a summary of oral antiplatelet drug hypo-responsiveness in patients with diabetes, specifically aspirin and clopidogrel resistance. Topics discussed include antiplatelet testing, definitions used to define hypo-response and resistance, its prevalence, association with clinical outcomes, and strategies to mitigate resistance. The role of prasugrel and ticagrelor, as well as investigational agents, is also discussed.

AB - Diabetes mellitus is a global pandemic, associated with a high burden of cardiovascular disease. There are multiple platelet derangements in patients with diabetes, and antiplatelet drugs remain the first-line agents for secondary prevention as well as for high-risk primary prevention among patients with diabetes. This review provides a summary of oral antiplatelet drug hypo-responsiveness in patients with diabetes, specifically aspirin and clopidogrel resistance. Topics discussed include antiplatelet testing, definitions used to define hypo-response and resistance, its prevalence, association with clinical outcomes, and strategies to mitigate resistance. The role of prasugrel and ticagrelor, as well as investigational agents, is also discussed.

KW - Antiplatelet

KW - Antiplatelet resistance

KW - Aspirin resistance

KW - Clopidogrel resistance

KW - Diabetes mellitus

KW - High on-treatment platelet reactivity

KW - Platelets

UR - http://www.scopus.com/inward/record.url?scp=84961315271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961315271&partnerID=8YFLogxK

U2 - 10.1007/s12170-014-0430-5

DO - 10.1007/s12170-014-0430-5

M3 - Article

C2 - 25844111

AN - SCOPUS:84961315271

VL - 9

JO - Current Cardiovascular Risk Reports

JF - Current Cardiovascular Risk Reports

SN - 1932-9520

IS - 2

ER -